3-D Transcranial Ultrasound Analysis Study

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

December 31, 2013

Conditions
Cerebrovascular AccidentIntracranial Hypertension
Interventions
DEVICE

3-D ultrasound scanner

The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.

DRUG

Perflutren Protein-Type A Microspheres for injection

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER

NCT00239525 - 3-D Transcranial Ultrasound Analysis Study | Biotech Hunter | Biotech Hunter